Cidara Therapeutics Inc (CDTX) Stock Analysis

Cidara Therapeutics Inc (CDTX) is a publicly traded company in the HEALTHCARE sector. It trades at $221.38. This page summarizes the public market data, fundamentals, and frequently asked questions for CDTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Cidara Therapeutics Inc currently has a Neutral sentiment score of 0.08.

About Cidara Therapeutics Inc

Cidara Therapeutics, Inc. is a forward-thinking biotechnology firm headquartered in San Diego, California, focused on advancing long-acting anti-infective therapies to tackle critical unmet medical needs in infectious diseases. Utilizing its proprietary Cloudbreak™ platform, Cidara is at the forefront of developing innovative treatments that aim to improve patient outcomes and increase treatment adherence. The company's diverse pipeline encompasses promising therapeutics targeting both fungal...

GNG Research Analysis

GNG Research scores Cidara Therapeutics Inc (CDTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CDTX.

Frequently Asked Questions

Does CDTX pay dividends?

Cidara Therapeutics Inc (CDTX) does not currently pay a regular dividend.